Wells Fargo Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Halozyme Therapeutics (NASDAQ:HALO) and raises the price target from $48 to $58.
June 07, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Halozyme Therapeutics and raises the price target from $48 to $58.
The raised price target and maintained Overweight rating from a reputable analyst at Wells Fargo is likely to positively impact investor sentiment and drive short-term price appreciation for HALO.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100